Octreotide therapy in carcinoid disease

Area of Science:

• Endocrinology
• Oncology
• Pharmacology

Background:

• Carcinoid syndrome presents with debilitating symptoms such as flushing and diarrhea.
• Current therapeutic options for carcinoid syndrome are limited, with significant unmet needs.
• Octreotide and other somatostatin analogues represent a key pharmacological approach.

Purpose of the Study:

• To evaluate the efficacy of octreotide and somatostatin analogues in managing carcinoid syndrome.
• To assess the role of these agents in symptom control versus disease modification.
• To determine the perioperative utility of octreotide in carcinoid disease management.

Main Methods:

• Review of published studies on octreotide and somatostatin analogue therapy for carcinoid syndrome.
• Analysis of symptom control, tumor growth, survival data, and perioperative use.
• Assessment of evidence quality, noting limitations such as small patient numbers and lack of control groups.

Main Results:

• Octreotide and somatostatin analogues are effective in controlling flushing and diarrhea associated with carcinoid syndrome.
• Evidence for effects on tumor growth or survival remains inconclusive.
• These agents are vital for perioperative cardiovascular and respiratory stability.

Conclusions:

• Octreotide and somatostatin analogues are the current treatments of choice for symptomatic control of carcinoid syndrome.
• Their primary role is symptom management, not disease modification or improved survival.
• Availability of octreotide in operating rooms is essential for surgical management of carcinoid disease.